Antimicrobial susceptibility against penicillin, ampicillin and vancomycin of viridans group Streptococcus in oral microbiota of patients at risk of infective endocarditis.
The viridans group Streptococci (VGS) are most abundant in the mouth; in some instances they might emerge as pathogens particularly in infective endocarditis (IE). In this study, we aimed to define and determine the susceptibility against antibiotics of VGS that are members of the oral microbiota of patients exhibiting a risk of developing IE. Forty-nine patients at risk of infective endocarditis were included in the study. Identification of the bacteria was performed using API STREP (bioMérieux, France). Gradient test strips (E-Test, France) were used to determine MIC of the bacteria against penicillin, ampicillin, and vancomycin. The distribution of the isolated VGS groups was determined as follows: Streptococcus mitis 32.6% and anginosus group - 32.6%, S. sanguinis group - 16.3%, S. mutans group - 12.2%, and S. salivarius group - 6.1%. The rates of resistance and reduced sensitivity of the isolates for penicillin and ampicillin were determined at 61.2% and 55.1%, respectively. However, all isolates were found to be susceptible to vancomycin. We conclude that the antimicrobial resistance of VGS should be determined on a regular basis locally, and decisions on therapeutic and prophylactic interventions should be given taking this resistance into consideration.
Public Health Institute of Turkey, National Antimicrobial Resistance Laboratory, Ankara, Turkey.
Serap
S
Süzük
Banu Kaşkatepe, University of Ankara, Faculty of Pharmacy, Department of Pharmaceutical Microbiology, Ankara, Turkey.
Banu
B
Kaşkatepe
Ankara Numune Training and Research Hospital, Department of Cardiology, Ankara, Turkey.
Mustafa
M
Çetin
D000328:Adult; D000667:Ampicillin / Q000494:pharmacology*; D024901:Drug Resistance, Multiple, Bacterial; D004697:Endocarditis, Bacterial / Q000382:microbiology / Q000517:prevention & control*; D005260:Female; D006350:Heart Valve Prosthesis / Q000009:adverse effects; D006801:Humans; D008297:Male; D064307:Microbiota; D008875:Middle Aged; D009055:Mouth / Q000382:microbiology*; D010406:Penicillins / Q000494:pharmacology*; D016459:Prosthesis-Related Infections / Q000382:microbiology / Q000517:prevention & control; D012306:Risk; D013045:Species Specificity; D013290:Streptococcal Infections / Q000382:microbiology / Q000517:prevention & control*; D014421:Turkey / Q000453:epidemiology; D014640:Vancomycin / Q000494:pharmacology*; D034363:Viridans Streptococci / Q000187:drug effects*
D010406:Penicillins; D014640:Vancomycin; D000667:Ampicillin